Mink Therapeutics Stock Gross Profit

INKT Stock

USD 0.68 0.01 1.45%

Mink Therapeutics fundamentals help investors to digest information that contributes to Mink Therapeutics' financial success or failures. It also enables traders to predict the movement of Mink Stock. The fundamental analysis module provides a way to measure Mink Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mink Therapeutics stock.

	Last Reported	Projected for Next Year
Gross Profit	-204.6 K	-214.8 K
Gross Profit Margin	(9.40)	(9.87)

Gross Profit is likely to drop to about (214.8 K) in 2024. Gross Profit Margin is likely to drop to -9.87 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Mink Therapeutics Company Gross Profit Analysis

Mink Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Current Mink Therapeutics Gross Profit

(214.8K)

Most of Mink Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mink Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Mink Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Mink Therapeutics is extremely important. It helps to project a fair market value of Mink Stock properly, considering its historical fundamentals such as Gross Profit. Since Mink Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mink Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mink Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Surpluse
Total Assets		0.91	0.79	0.05	-0.87	-0.45	0.45	0.59	-0.61	-0.64	0.91	1.0	0.67	0.97	0.05	0.67	0.4	0.05
Total Stockholder Equity	0.91		0.96	-0.2	-0.99	-0.63	0.54	0.57	-0.59	-0.9	0.74	0.9	0.83	0.91	-0.2	0.83	0.57	-0.2
Net Tangible Assets	0.79	0.96		-0.47	-0.98	-0.8	0.61	0.67	-0.69	-0.93	0.53	0.78	0.93	0.76	-0.47	0.93	0.7	-0.47
Current Deferred Revenue	0.05	-0.2	-0.47		0.34	0.75	-0.41	-0.44	0.53	0.4	0.39	0.07	-0.59	0.16	1.0	-0.59	-0.49	1.0
Net Debt	-0.87	-0.99	-0.98	0.34		0.75	-0.65	-0.67	0.69	0.91	-0.63	-0.86	-0.91	-0.84	0.34	-0.91	-0.68	0.34
Retained Earnings	-0.45	-0.63	-0.8	0.75	0.75		-0.83	-0.86	0.87	0.68	-0.03	-0.43	-0.96	-0.31	0.75	-0.96	-0.91	0.75
Accounts Payable	0.45	0.54	0.61	-0.41	-0.65	-0.83		0.75	-0.78	-0.52	0.09	0.44	0.81	0.34	-0.41	0.81	0.85	-0.41
Long Term Debt	0.59	0.57	0.67	-0.44	-0.67	-0.86	0.75		-0.97	-0.43	0.23	0.57	0.85	0.41	-0.44	0.85	0.84	-0.44
Net Receivables	-0.61	-0.59	-0.69	0.53	0.69	0.87	-0.78	-0.97		0.43	-0.26	-0.6	-0.85	-0.43	0.53	-0.85	-0.76	0.53
Total Liab	-0.64	-0.9	-0.93	0.4	0.91	0.68	-0.52	-0.43	0.43		-0.42	-0.63	-0.82	-0.67	0.4	-0.82	-0.65	0.4
Net Invested Capital	0.91	0.74	0.53	0.39	-0.63	-0.03	0.09	0.23	-0.26	-0.42		0.91	0.3	0.95	0.39	0.3	0.01	0.39
Total Current Assets	1.0	0.9	0.78	0.07	-0.86	-0.43	0.44	0.57	-0.6	-0.63	0.91		0.65	0.98	0.07	0.65	0.38	0.07
Capital Stock	0.67	0.83	0.93	-0.59	-0.91	-0.96	0.81	0.85	-0.85	-0.82	0.3	0.65		0.57	-0.59	1.0	0.89	-0.59
Net Working Capital	0.97	0.91	0.76	0.16	-0.84	-0.31	0.34	0.41	-0.43	-0.67	0.95	0.98	0.57		0.16	0.57	0.29	0.16
Short Term Debt	0.05	-0.2	-0.47	1.0	0.34	0.75	-0.41	-0.44	0.53	0.4	0.39	0.07	-0.59	0.16		-0.59	-0.49	1.0
Common Stock	0.67	0.83	0.93	-0.59	-0.91	-0.96	0.81	0.85	-0.85	-0.82	0.3	0.65	1.0	0.57	-0.59		0.89	-0.59
Property Plant Equipment	0.4	0.57	0.7	-0.49	-0.68	-0.91	0.85	0.84	-0.76	-0.65	0.01	0.38	0.89	0.29	-0.49	0.89		-0.49
Capital Surpluse	0.05	-0.2	-0.47	1.0	0.34	0.75	-0.41	-0.44	0.53	0.4	0.39	0.07	-0.59	0.16	1.0	-0.59	-0.49

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Mink Therapeutics

Gross Profit Over Time

Mink Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mink Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mink Therapeutics could also be used in its relative valuation, which is a method of valuing Mink Therapeutics by comparing valuation metrics of similar companies.

Mink Therapeutics is currently under evaluation in gross profit category among its peers.

Mink Fundamentals

	Return On Equity	-12.39
	Return On Asset	-0.97
	Current Valuation	25.18 M
	Shares Outstanding	39.55 M
	Shares Owned By Insiders	74.64 %
	Shares Owned By Institutions	2.25 %
	Number Of Shares Shorted	51.73 K
	Price To Book	10.05 X
	EBITDA	(22.25 M)
	Net Income	(22.46 M)
	Cash And Equivalents	29.85 M
	Cash Per Share	0.88 X
	Total Debt	22.61 M
	Current Ratio	1.74 X
	Book Value Per Share	(0.52) X
	Cash Flow From Operations	(15.76 M)
	Short Ratio	1.10 X
	Earnings Per Share	(0.37) X
	Target Price	6.67
	Number Of Employees	31
	Beta	0.048
	Market Capitalization	26.89 M
	Total Asset	4.55 M
	Retained Earnings	(133.4 M)
	Working Capital	(7.8 M)
	Net Asset	4.55 M

About Mink Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mink Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mink Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mink Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC